[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607185":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":40,"studyPopulation":24,"armGroups":41,"interventions":74,"overallOfficials":24,"centralContacts":85,"locations":91,"responsibleParty":111,"collaborators":24,"id":113,"slug":24,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":24,"eligibilityCriteria":118,"healthyVolunteers":114,"sex":119,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":24,"studyType":125,"phases":126,"briefSummary":129,"conditions":130,"keywords":24,"overallStatus":94,"whyStopped":24,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},{"fullName":5,"class":6},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Number of participants with Adverse Events","Incidence of adverse events will be summarized by SOC and PT for each treatment group, and also be summarized by severity and association with the study treatments.","During the 32- or 36-week study period",[14,18],{"measure":15,"description":16,"timeFrame":17},"SLE Responder Index (SRI-4)","Proportion of subjects achieving an SLE Responder Index (SRI-4) response","During the 20- or 24-week treatment period",{"measure":19,"description":20,"timeFrame":17},"BILAG-based Combined Lupus Assessment (BICLA) Response","Proportion of patients achieving a BILAG-based Combined Lupus Assessment (BICLA) response",[22,25,27],{"measure":23,"description":24,"timeFrame":12},"Peak Plasma Concentration (Cmax)",null,{"measure":26,"description":24,"timeFrame":12},"Area under the Concentration-Time Curve up to the Last Measurable Concentration（AUC0-last）",{"measure":28,"description":24,"timeFrame":12},"Time to Peak Concentration（Tmax ）",{"allocation":30,"interventionModel":31,"interventionModelDescription":24,"primaryPurpose":32,"observationalModel":24,"timePerspective":24,"maskingInfo":33},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":34,"maskingDescription":24,"whoMasked":35},"QUADRUPLE",[36,37,38,39],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with heterogeneous manifestations and disease course. Despite advances in medical care, there are still significant unmet needs in SLE with persistent disease activity, disease flares, intolerance to standard of care (SOC) therapies, and development of organ damage and co-morbidities.\n\nThe purpose of this study is to demonstrate the clinical efficacy and safety of 626 added to standard of care (SoC) therapy compared to placebo with SoC therapy in subjects with SLE.",[42,49,53,57,61,65,69],{"label":43,"type":44,"description":45,"interventionNames":46},"Group M1","EXPERIMENTAL","dose level 1 of 626",[47,48],"Drug: 626","Drug: Placebo",{"label":50,"type":44,"description":51,"interventionNames":52},"Group M2","dose level 2 of 626",[47,48],{"label":54,"type":44,"description":55,"interventionNames":56},"Group M3","dose level 3 of 626",[47,48],{"label":58,"type":44,"description":59,"interventionNames":60},"Group M4","dose level 4 of 626",[47,48],{"label":62,"type":44,"description":63,"interventionNames":64},"626 Dose A","626 Dose A subcutaneous (SC) injection.",[47],{"label":66,"type":44,"description":67,"interventionNames":68},"626 Dose B","626 Dose B subcutaneous (SC) injection",[47],{"label":70,"type":71,"description":72,"interventionNames":73},"Placebo","PLACEBO_COMPARATOR","Placebo subcutaneous (SC) injection.",[48],[75,80,83],{"type":76,"name":77,"description":78,"armGroupLabels":79,"otherNames":24},"DRUG","626","626 subcutaneous (SC) injection. Placebo subcutaneous (SC) injection.",[43,50,54,58],{"type":76,"name":77,"description":81,"armGroupLabels":82,"otherNames":24},"626 subcutaneous (SC) injection.",[62,66],{"type":76,"name":70,"description":72,"armGroupLabels":84,"otherNames":24},[43,50,54,58,70],[86],{"name":87,"role":88,"phone":89,"phoneExt":24,"email":90},"Qinghong Zhou","CONTACT","+86 18911301578","zhouqinghong@3sbio.com",[92],{"facility":93,"status":94,"city":95,"state":96,"zip":97,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":105,"contacts":106},"Peking Union Medical College Hospital","RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":101,"coordinates":102},"Point",[103,104],116.39723,39.9075,{"lat":104,"lon":103},[107],{"name":108,"role":88,"phone":109,"phoneExt":24,"email":110},"Mengtao Li","+86 13911788572","Mengtao.li@cstar.org.cn",{"type":112,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100607185",false,"NCT07185269","The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib\u002FII Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Anti-BDCA2 Antibody SSGJ-626 in Subjects With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* Able to understand protocol requirements and sign a written ICF.\n* Male or female subjects aged 18-70 years when signing the ICF.\n* Body weight between 40 and 90 kg.\n* Diagnosed with SLE at least 6 months before the Screening Visit by a qualified physician，confirmed according to the 2019 SLE European League Against Rheumatism\u002FAmerican College of Rheumatology (EULAR\u002FACR) classification criteria for SLE.\n* At screening, meet at least one of the following criteria:\n\n  1. Anti-nuclear antibody (ANA) titer ≥ 1:80;\n  2. Positive anti-dsDNA antibody..\n* Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≥6 with clinical SLEDAI score ≥4 points at Screening and Baseline Visit .\n* Currently receiving at least one of the SOC SLE medications: oral corticosteroid, antimalarial and\u002For immunosuppressive agent.\n\nExclusion Criteria:\n\n* Study participant has a mixed connective tissue disease, and\u002For overlap syndrome of systemic lupus erythematosus (SLE) with systemic sclerosis.\n* Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric SLE) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition\n* Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.\n* History of cancer.\n* Active severe lupus nephritis present within 2 months prior to baseline. Or estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2, or protein:creatinine ratio \\>2.0 g\u002Fg.","ALL","18 Years","70 Years",{"count":123,"type":124},198,"ESTIMATED","INTERVENTIONAL",[127,128],"PHASE1","PHASE2","This study will evaluate the effect and safety of 626 in patients with SLE",[131],"Systemic Lupus Erythematosus (SLE)","2025-11-25",{"date":134,"type":135},"2025-11-26","ACTUAL",{"date":137,"type":135},"2025-09-24",{"date":139,"type":124},"2028-11-04",{"name":5,"class":6},1]